On Schrodinger

 From the Fool (recommends and owns shares):

Unless you work in the biopharmaceutical industry, you've probably never heard of Schrodinger (NASDAQ:SDGR). The company provides a platform that helps biopharmaceutical companies discover new treatments more quickly than traditional methods. The company's software-as-a-service platform, which incorporates physics, data analytics, predictive analysis, and artificial intelligence, performs state-of-the-art simulations that lead to quicker and cheaper drug development and the discovery of novel treatment options. 

Backed by Bill Gates, Schrodinger went public early last year, and the small company has had an impressive start. In 2020, revenue grew 26% year over year, driven by software revenue that increased 39%. Gross profit grew 29%, which helps illustrate the scalability of the company's model, though it's currently still unprofitable. 

Its customer metrics are equally impressive. Last year, the number of customers with $1,000 in annual contract value (ACV) grew 16%, while those with ACV of $100,000 grew at 17%. More importantly, however, is that large customers with ACV of more than $1 million grew by 60%, and customer retention clocked in a 99%. If these trends continue, the company has a bright future.

Wood has been consistently adding to the ARK Genomic Revolution (NYSEMKT:ARKG) ETF's position in Schrodinger. With last week's purchases, the company has become a Top 20 position, representing nearly 2% of the $7.67 billion in assets under management.

Schrodinger is sitting in the catbird seat, at the heart of the digital transformation of drug discovery, and with a market cap of just $5 billion, it's easy to envision a path where Schrödinger could grow tenfold.

Catherine Wood Buys Trimble and the Fool Owns Shares

 According to this article, the Fool and Wood have purchased shares. 

3 Growth ETF

 The Fool has identified three growth ETFs that may warrant a look. 

Keep an Eye On Nelnet

 Nelnet is a small cap conglomerate that has its hands in many small businesses.  It's primary source of income is interest from student loans, but it also owns a payment network that many colleges and secondary schools use.  It pays a dividend and the Fool owns shares. 

On OptimizeRX

 The Fool and TipRanks are bullish on OptimizeRX.  This is a small company with a valuation of under $1billion that has room to run.   

2 SPACs to Buy Right Now

 The Fool highlights two SPACs to buy:  IPOE and GHVI. 

Looking at Guardant Health

 The Fool looks at Guardant Health, which they have pegged as the leader in liquid biopsies.  They have several products on the market and will launch additional products this year. 

Waiting for Marqueta to go Public

One Fool is waiting for Marqueta to go public, which may happen around April.  He explains why it is a top IPO stock to look forward to.  

My Top Stock to Own for the Next 10 Years

 CareTrust REIT is this Fool's top stock to own for the next 10 years. 

On Vive Medical

 

This company’s products are very much in demand from women. Viveve Medical Inc. (NASDAQ: VIVE) designs, develops, manufactures and markets medical devices for the noninvasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation and stress urinary incontinence.

The Viveve System includes a radio frequency generator, reusable hand piece and treatment tip, as well as cryogen canister and other consumable components. The company markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East and Latin America.

The noninvasive, endovaginal Viveve system has been cleared and is marketed (by distribution partners) in more than 50 countries for a variety of noninvasive female health indications. The system also gained FDA clearance in late 2016, but only with a general surgical label. As of the end of third quarter 2020, the company had an installed base of 479 systems in the United States and 386 internationally.

Alliance Global has set a giant $10.75 target price. That compares with the much higher consensus target of $22. The stock has traded near $3.50 recently.